Chinese Journal of Tissue Engineering Research ›› 2024, Vol. 28 ›› Issue (9): 1464-1469.doi: 10.12307/2024.004

Previous Articles     Next Articles

Signaling pathway of dexmedetomidine against ischemia-reperfusion injury

Yang Yifeng, Ye Nan, Wang Lin, Guo Shuaicheng, Huang Jian   

  1. Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China
  • Received:2023-01-17 Accepted:2023-02-24 Online:2024-03-28 Published:2023-07-26
  • Contact: Huang Jian, MD, Chief physician, Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China
  • About author:Yang Yifeng, Master, Attending physician, Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China
  • Supported by:
    Young People's Program of Inner Mongolia Medical University, No. YKD2022QN034 (to YYF); 2022 Inner Mongolia Autonomous Region Health Science and Technology Plan Project, No. 202201352 (to HJ)

Abstract: BACKGROUND: Dexmedetomidine has the effect of anti-ischemia-reperfusion injury, but the comprehensive and systematic review of its signaling pathway is less.  
OBJECTIVE: To focus on the review of dexmedetomidine’s signaling pathway in the mechanisms of antioxidant stress, inhibition of inflammation, anti-apoptosis, autophagy, and so on.
METHODS: The relevant articles on PubMed, CNKI, WanFang, and VIP databases were searched by computer with the key words “ischemia-reperfusion inquiry; dexmedetomidine; signal path; oxidative stress; inflammation; apoptosis” in Chinese and English. After excluding repetitive research and some basic articles with low correlation, 57 articles were finally included for review.  
RESULTS AND CONCLUSION: (1) Dexmedetomidine plays an important role in organ protection through many mechanisms, such as anti-oxidative stress injury, anti-inflammation, anti-apoptosis and autophagy. This involves many pathways, including Nrf2 and its downstream protein antioxidant stress pathway, Toll-like receptor 4 family and nuclear factor-κB-related anti-inflammatory pathway, JAK2/STAT3-related anti-inflammatory pathway, and cholinergic anti-inflammatory pathway, and the cholinergic pathway is the upstream mechanism of many nuclear factor-κB signaling pathways. (2) PI3K/Akt pathway plays different roles according to its activated downstream signals, inhibiting the activation of NLRP3 inflammatory body, activating signal molecules endothelial nitric oxide synthase, mammalian target of rapamycin, and hypoxia-inducible factor 1α to play an anti-inflammatory role, and activate Bad or Bax residues to play an anti-apoptotic role, and PI3K/Akt activates glycogen synthetase kinase-3β. It can also play an anti-inflammatory and anti-apoptotic role. (3) Dexmedetomidine activates SIRT3 to mediate anti-apoptosis and inhibit endoplasmic reticulum stress to produce anti-apoptosis. (4) The detailed review of the anti-ischemia-reperfusion injury signaling pathway of dexmedetomidine can provide a basis for future mechanism research and diagnosis and treatment decisions.

Key words: ischemia-reperfusion injury, dexmedetomidine, signaling pathway, oxidative stress, inflammation, apoptosis

CLC Number: